Mr. Jonathan Rigby reports

SERNOVA BIOTHERAPEUTICS APPOINTS JOHN L. BROOKS III, FORMER CHAIR AND CEO OF JOSLIN DIABETES RESEARCH CENTER, AS CHAIR OF THE BOARD OF DIRECTORS

Sernova Biotherapeutics Inc. has appointed John L. Brooks III as chair of the company's board of directors.

"We are honoured to have John lead our board at this exciting time for Sernova," said Jonathan Rigby, chief executive officer of Sernova. "His deep experience in T1D, venture capital and building early-stage companies will be invaluable as we advance our Cell Pouch Bio-hybrid Organ as a functional cure for T1D into the final cohort of our ongoing phase 1/2 clinical trial."

Mr. Brooks currently serves as managing director at Healthcare Capital LLC, where he advises early-stage life science companies and also as the CEO of Diamune that is developing innovative IgG Fc-Fusion insulin analogs. During his career, Mr. Brooks served as the chair and CEO of the Joslin Diabetes Center, the world's pre-eminent diabetes research, clinical care and education organization. Additionally, he has co-founded seven life science companies, including Insulet Corp. (Nasdaq: PODD), developer of the Omnipod tubeless insulin pump. He was previously a founder of Prism Venture Partners, a senior medical device executive at Pfizer and a senior manager at Arthur Andersen & Co. Mr. Brooks also serves on the boards of several T1D and population health organizations.

"I am thrilled to join Sernova at such an exciting moment in its journey," said Mr. Brooks. "The Cell Pouch Bio-hybrid Organ holds great potential for patients with T1D, and the integration of novel immunotherapies like tegoprubart could significantly improve the durability and effectiveness of islet cell transplantation. I look forward to working with the leadership team and board to help guide Sernova as we seek to provide T1D patients with a viable functional cure."

Mr. Brooks holds an M.S. in Business Administration and a bachelor of business administration from the University of Massachusetts at Amherst, where he graduated cum laude. He is also a certified public accountant.

About Sernova Biotherapeutics Inc.

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is composed of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

We seek Safe Harbor.